American Century Companies Inc. Purchases 16,653 Shares of Medpace Holdings, Inc. $MEDP

American Century Companies Inc. raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 131.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,370 shares of the company’s stock after acquiring an additional 16,653 shares during the period. American Century Companies Inc. owned about 0.10% of Medpace worth $15,101,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Clarkston Capital Partners LLC purchased a new position in shares of Medpace in the second quarter worth about $40,569,000. Cibc World Market Inc. purchased a new stake in Medpace during the 3rd quarter valued at about $5,033,000. Brighton Jones LLC boosted its holdings in Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after acquiring an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC grew its position in Medpace by 150.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock worth $8,080,000 after acquiring an additional 9,117 shares during the last quarter. Finally, Baillie Gifford & Co. increased its stake in Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after purchasing an additional 62,503 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 2.5%

Shares of MEDP stock opened at $466.79 on Wednesday. The firm has a market capitalization of $13.25 billion, a price-to-earnings ratio of 30.51, a PEG ratio of 2.29 and a beta of 1.44. The stock has a fifty day moving average of $530.07 and a 200 day moving average of $539.67. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. During the same period in the previous year, the firm earned $3.67 EPS. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on MEDP shares. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Truist Financial decreased their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. Royal Bank Of Canada began coverage on shares of Medpace in a report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price target for the company. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a research report on Friday, February 13th. Finally, Leerink Partners cut their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Five equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Medpace has a consensus rating of “Hold” and a consensus target price of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.